Hematology TimesRestrictions on pharma reps change docs’ prescribing behaviorMay 4, 2017PharmacyRelated Issues
Hematology TimesCompany withdraws MAA for vosaroxin in AMLMay 3, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesHeavily promoted drugs provide less ‘health value,’ study suggestsMay 3, 2017ThrombosisPharmacyRelated Issues
Hematology TimesFDA approves first ready-to-use oral solution of methotrexateMay 2, 2017Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyALL
Hematology TimesDrug receives orphan designation for AMLMay 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesFDA approves midostaurin to treat FLT3+ AML, advanced SMMay 1, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesEngland did not benefit from CDF, analysis suggestsApril 28, 2017PharmacyRelated Issues
Hematology TimesProgram allows select Europeans access to belinostatApril 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesFDA issues warnings about illegal ‘anticancer’ productsApril 26, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
Hematology TimesCHMP recommends inotuzumab ozogamicin for adult ALLApril 24, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Hematology TimesCHMP recommends approval for rituximab biosimilarApril 23, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesCAR T-cell therapy receives breakthrough designationApril 19, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesHealth Canada expands approval of daratumumab in MMApril 18, 2017Multiple MyelomaPharmacy
Hematology TimesFDA: REMS for ESAs no longer needed, though risks persistApril 14, 2017AnemiaPharmacy
